Vyome Holdings, Inc. — 10-Q Summary
Important issuer mismatch: The supplied filing is for Obalon Therapeutics, Inc., not Vyome Holdings, Inc. It reports the quarter ended September 30, 2018 and was signed November 2, 2018. The figures and disclosures below describe Obalon; verify the issuer before relying on this summary.
Business context and reporting period
Obalon was a vertically integrated medical-device company selling its FDA-approved, swallowable gas-filled intragastric balloon system. It began U.S. commercialization in January 2017 and sold primarily to U.S. physicians and institutions, as well as one Middle East distributor. The unaudited results cover the three and nine months ended September 30, 2018, compared with the same 2017 periods.
Financial results and liquidity
| Metric | Q3 2018 | Q3 2017 | Nine months 2018 | Nine months 2017 |
|---|---|---|---|---|
| Revenue | $3.0 million | $2.8 million | $7.1 million | $6.2 million |
| Gross profit | $1.6 million | $1.5 million | $3.1 million | $3.1 million |
| Gross margin | 53% | 53% | 45% | 50% |
| Operating expenses | $8.2 million | $10.6 million | $31.5 million | $27.6 million |
| Operating loss | $6.6 million | $9.1 million | $28.3 million | $24.5 million |
| Net loss | $6.7 million | $9.2 million | $28.6 million | $24.6 million |
| Basic and diluted loss per share | $0.35 | $0.55 | $1.60 | $1.48 |
At September 30, 2018, cash and cash equivalents were $21.6 million and short-term investments were $8.1 million, totaling $29.7 million. Current assets were $35.3 million and current liabilities $7.3 million. Accumulated deficit was $140.0 million.
Operating cash outflow for the first nine months was $24.0 million, versus $21.4 million in 2017. Investing activities provided $14.3 million, primarily from investment maturities; financing activities provided $10.1 million, mainly from the August stock placement. Cash increased $0.4 million from year-end 2017.
Term-loan principal outstanding was $10.0 million, with a carrying amount of $9.9 million before current/noncurrent presentation. The loan bears variable interest at prime plus 1.5% (6.75% at September 30), matures in July 2022, and has interest-only payments through July 9, 2019. An additional $10.0 million tranche was available through July 9, 2019. The loan is secured by substantially all assets other than intellectual property and includes operating restrictions.
Material changes versus the prior comparable period
- Revenue grew 7% in Q3 and 14% for the nine-month period. Growth came from higher sales to the Middle East distributor; U.S. revenue declined by $0.2 million in Q3 and $1.5 million over nine months.
- Management attributed distributor growth to increased unit sales, including commercialization of the six-month balloon, but said distributor sales carried a lower transfer price. Nine-month gross margin consequently fell to 45% from 50%; Q3 margin held at 53%.
- Q3 operating expenses declined 23%, chiefly because 2017 included a $1.4 million noncash charge for a patent-litigation settlement and because marketing, commissions, and stock compensation were lower. Nine-month operating expenses rose 14%, including increased legal and investigation costs, marketing, stock compensation, payroll, and clinical-trial spending.
- Net loss improved in Q3 but widened for the nine-month period. The August private placement raised $10.0 million gross through issuance of 5,494,506 shares.
- Cash and short-term investments fell from $44.4 million at December 31, 2017 to $29.7 million at September 30, 2018, while outstanding loan principal was $10.0 million.
Outlook, risks, contingencies, and unusual items
- Management expected existing cash, available debt capacity, and anticipated revenue to fund operations for at least 12 months from the filing date. It also planned to seek further debt or equity financing; funding might not be available on acceptable terms or at all. Management expected continued losses and substantial spending on U.S. commercialization, market development, manufacturing, and R&D.
- Customer concentration is significant: the Middle East distributor accounted for 39.4% of Q3 revenue and 45.4% of nine-month revenue. A separate U.S. customer represented 27.4% and 18.2%, respectively. Management said this U.S. customer had indicated it might reduce or discontinue purchases. The distributor agreement was due to expire December 31, 2019.
- The FDA approved the Obalon Touch Inflation System in September 2018. The Obalon Navigation System remained unapproved; after a late-October major deficiency letter requesting additional information, analysis, and clarification, the company targeted an FDA decision in Q1 2019 but cautioned timing and outcome were uncertain.
- Shareholder class-action litigation was at a preliminary stage. An amended complaint filed October 5, 2018 alleged securities-law violations and sought damages and other relief; the company said it intended to defend vigorously. The filing reported no related accrual for the terminated January stock offering and said management considered material future fees from that matter remote.
- Key business risks include the immature self-pay market, reliance on one product and a concentrated distributor/customer base, competition, manufacturing scale-up and single-source suppliers, product safety and liability exposure, regulatory approvals and post-approval requirements, and the need for additional capital. The filing describes serious adverse events associated with intragastric balloons, including reported events involving Obalon products; FDA warnings cited in the filing concerned liquid-filled balloons.
- The company adopted ASC 606 in 2018; it reported no material impact on results. Management said disclosure controls were effective at the reasonable-assurance level and reported no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Confirm that Obalon Therapeutics, Inc.—not Vyome Holdings, Inc.—is the intended issuer and that this is the correct filing.
- Check subsequent revenue, order trends, and customer concentration, especially the Middle East distributor and the U.S. customer considering reduced or discontinued purchases.
- Review subsequent cash burn, financing, use and availability of the additional loan tranche, loan covenants, and actual operating runway.
- Verify FDA progress and any commercial launch plans for the Navigation System, and monitor clinical, safety, and post-approval-study disclosures.
- Track developments and any financial consequences of the shareholder lawsuit and the prior offering-related investigation.